Abstract
Breast cancer is a hormone-dependent cancer, and sex steroids play a pivotal role in breast cancer progression. Estrogens are strongly associated with breast cancers, and the estrogen receptor (estrogen receptor α; ERα) is expressed in 70–80% of human breast carcinoma tissues. Although antiestrogen therapies (endocrine therapies) have significantly improved clinical outcomes in ERα-positive breast cancer patients, some patients experience recurrence after treatment. In addition, patients with breast carcinoma lacking ERα expression do not benefit from endocrine therapy. The androgen receptor (AR) is also expressed in >70% of breast carcinoma tissues. Growing evidence supports this novel therapeutic target for the treatment of triple-negative breast cancers that lack ERα, progesterone receptor, and human EGF receptor 2, and ERα-positive breast cancers, which are resistant to conventional endocrine therapy. However, the clinical significance of AR expression is still controversial and the biological function of androgens in breast cancers is unclear. In this review, we focus on the recent findings concerning androgen action in breast cancers and the contributions of androgens to improved breast cancer therapy.
Introduction
Breast cancer is the most common malignancy in women. Breast cancer is not a single disease but a heterogeneous disease with highly complicated gene expression profiles. Sex steroids are associated with the biological features of breast cancers, and estrogens significantly contribute to breast cancer progression. Antiestrogen therapies, such as selective estrogen receptor (ER) modulators (SERMs) like tamoxifen, selective ER degraders like fulvestrant, aromatase inhibitors (AIs), and luteinizing hormone-releasing hormone agonists, are currently available and improve clinical outcomes in ERα-positive breast cancer patients. However, acquired endocrine therapy resistance leads to recurrence in up to 20% of patients with ERα-positive breast cancers (Waks & Winer 2019). Triple-negative breast cancers (TNBCs) lack ERα, progesterone receptor (PR), and human EGF receptor 2 (HER2). High-risk breast cancers like TNBCs are also treated with chemotherapy, but 25% of patients develop distant recurrence after adjuvant chemotherapy (Tevaarwerk et al. 2013). Therefore, new therapeutic targets for breast cancers are being explored.
In addition to ERα, the androgen receptor (AR) is also expressed in 70–90% of breast carcinomas (Takagi et al. 2018). Although androgens suppress the growth of breast cancers, growing evidence supports a pro-tumorigenic role for androgens in both ERα-positive and ERα-negative breast cancers. Thus, AR is a potential new therapeutic target in breast cancers. In this review, we summarize recent findings concerning the role and regulation of androgens in breast cancers.
Intratumoral synthesis and metabolism of androgens
Dihydrotestosterone (DHT) has the highest affinity for AR and causes nuclear translocation of AR, leading to activation of transcriptional activity. Interestingly, tissue concentrations of DHT are higher in breast carcinoma tissues than in non-neoplastic breast tissues (Shibuya et al. 2008), indicating intratumoral DHT synthesis in breast carcinoma tissues. To better understand the intratumoral synthesis of androgens in human malignancies, tissue concentrations of androgens should be measured by accurate and sensitive methods, such as mass spectrometry-based assays (Shibuya et al. 2008, Takagi et al. 2010, Tanaka et al. 2015, Choi 2018, Hashimoto et al. 2018), and the enzymes responsible for androgen synthesis should be immunolocalized (Fig. 1). Of note, these enzymes are expressed regardless of ERα status and DHT may be synthesized in both ERα-positive and ERα-negative breast carcinoma tissues (Suzuki et al. 2001, 2005).
Scheme of intratumoral androgen synthesis. Dihydrotestosterone (DHT), a biologically active androgen, is locally produced by enzymes such as 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5) and 5α-reductase 1 (5αRed1). Aromatase negatively regulates intratumoral DHT synthesis by converting testosterone (T) to estradiol (E2). DHT is metabolized to 5α-androstane-3β,17β-diol (3β-diol), which possesses estrogenic effects. A4, androstenedione; E1, estrone.
Citation: Endocrine Oncology 2, 1; 10.1530/EO-22-0048
The circulating adrenal androgen, androstenedione, is converted to testosterone by 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5), a member of the aldo-keto reductase superfamily known as AKR1C3. Testosterone is then reduced to the biologically active androgen, DHT, by 5α-reductase (5αRed). In addition to testosterone synthesis, 17βHSD5 also has 3αHSD and 3βHSD activities (Steckelbroeck et al. 2004) that contribute to DHT metabolism to 5α-androstane-3β,17β-diol (3β-diol). Of note, 3β-diol acts as an estrogen rather than an androgen, and activation of ERα by 3β-diol is closely associated with resistance to endocrine therapy (Hanamura et al. 2013, 2016, described in more detail later). In addition, 17βHSD5 acts as a prostaglandin (PG) F2α synthase and reduces PGD2 to 11β-PGF2α (Yoda et al. 2015), which promotes proliferation and epithelial–mesenchymal transition (EMT) of breast cancers (Yoda et al. 2015). However, conflicting data concerning expression levels of 17βHSD5 in breast carcinoma tissues have been reported; thus, the role of 17βHSD5 is unclear. Recent public database analysis revealed that 17βHSD5 (AKR1C3) mRNA expression is decreased in breast cancer tissue compared to normal breast tissues (Yin et al. 2014) but is significantly upregulated in tamoxifen-resistant breast cancers (Xu et al. 2021).
The expression of 5αRed, which reduces testosterone to DHT, is elevated in breast carcinoma tissues compared to non-neoplastic breast tissues (Li et al. 2020). To date, three isoforms of 5αRed have been identified (5αRed1–3). Immunoreactivity toward 5αRed1 is frequently (58%) observed in breast carcinoma tissues, and 5αRed1 mRNA levels are eight-fold higher in breast carcinoma tissues compared with expression in non-neoplastic breast tissues. Immunoreactivity toward 5αRed2 is less frequent (15%) in breast carcinoma tissues compared with 5αRed1 (Suzuki et al. 2001), although 5αRed2 mRNA levels are higher in breast carcinoma tissues compared with expression levels in non-neoplastic breast tissues (Suzuki et al. 2001). In addition, we demonstrated that intratumoral DHT concentrations significantly correlate with 5αRed1 but not 5αRed2 immunoreactivity (Suzuki et al. 2007). Thus, 5αRed1 is mainly responsible for intratumoral DHT synthesis in breast cancers. In 2008, 5αRed3 was identified in prostate carcinoma tissues (Uemura et al. 2008). The contribution of 5αRed3 to DHT synthesis and the clinical significance of 5αRed3 in breast cancer are largely unclear. However, a recent database analysis showed that overexpression of 5αRed3 correlates with lymph node metastasis and shorter overall survival of breast cancer patients (Zhang et al. 2021). In contrast, 5αRed1 negatively correlates with histological grade and tumor size in breast carcinomas (Suzuki et al. 2001).
Aromatase converts testosterone to estradiol (E2). Thus, aromatase negatively regulates intratumoral DHT synthesis in breast cancer tissues. DHT concentrations are higher in ductal carcinoma in situ (DCIS) than in invasive ductal carcinoma tissues, where aromatase expression is higher compared to DCIS tissues (Shibuya et al. 2008). The AI, 4-hydroxyandrostenedione, increases intratumoral testosterone concentrations in a mammary breast cancer model (Spinola et al. 1988). The AI, letrozole, increases intraovarian testosterone concentrations in women and is widely used for endocrine therapy in breast cancers (Garcia-Velasco et al. 2005). Furthermore, we have previously reported that intratumoral DHT concentrations are significantly higher in breast cancer tissues after neoadjuvant AI exemestane therapy compared with the levels in tissues without exemestane therapy (Takagi et al. 2010). Exemestane also increases DHT production in human prostate microsomes measured with gas chromatography–mass spectrometry (Amaral et al. 2020). Therefore, intratumoral DHT synthesis and the expression of androgen-responsive genes are upregulated following AI treatment (Takagi et al. 2010, 2018).
AR–ERα crosstalk in ERα-positive breast cancer
Activation of steroid receptors is initiated by ligand binding to the C-terminal ligand binding domain, which triggers steroid receptor translocation to the nucleus. Nuclear steroid receptors act as transcriptional factors by binding to enhancer regions, including the estrogen-responsive element (ERE) and androgen-responsive element. Thus, the actions of sex steroids are achieved through gene regulation. ERα and AR are co-expressed and directly interact with each other in breast cancer cells (D’Amato et al. 2016). Thus, crosstalk between ERα and AR and the resulting alterations in gene expression are hot topics for investigation. Recent studies indicate that estrogen/ERα signaling is suppressed by androgen/AR. For example, DHT significantly suppresses E2-induced gene signatures of cell cycle regulation in a patient-derived explant model from ERα-positive breast cancers (Hickey et al. 2021). A recent genome-wide analysis also revealed that ERα occupancy on EREs is decreased after AR activation (Ponnusamy et al. 2019) due to shared transcriptional coactivators. Steroid receptors often share coregulators and competition for cofactors occurs when cofactor levels are limited (cofactor squelching). For instance, mediator complex subunit 1 (MED1) has two LXXLL motifs and interacts with several nuclear receptors, including ERα and AR, to stimulate transcriptional activity (Weber & Garabedian 2018). AIB1/Src3 is a coactivator of ERα and is recruited to the CCND1 gene promoter in MCF-7 breast cancer cells treated with E2; AIB1/Src3 recruitment is significantly suppressed by DHT (De Amicis et al. 2019). On the other hand, AR transactivation is also suppressed by estrogen (Rahim & O’Regan 2017), and we demonstrated that induction of androgen-responsive genes (PSA, HSD17B2) is suppressed by E2 (Suzuki et al. 2010, Takagi et al. 2010). In addition, we demonstrated that expression levels of approximately one-third of putative androgen-responsive genes are increased in response to AI treatment, which increases intratumoral DHT synthesis (Takagi et al. 2018). Interestingly, AR and ERα can also cooperate. For example, the expression levels of the UDP-glucuronosyltransferases, UGT2B15 and UGT2B17, are regulated by tandem binding of AR and ERα at their proximal promoter, and DHT-induced UGT2B15 and UGT2B17 expression levels are significantly suppressed by both antiestrogen fulvestrant and antiandrogen flutamide in MCF-7 cells (Hu et al. 2016). Furthermore, the second-generation antiandrogen, enzalutamide, inhibits chromatin binding of both AR and ERα, suggesting that AR is necessary for maximum chromatin binding of ERα (D’Amato et al. 2016). E2 also induces chromatin binding of AR, but the binding sites are unique compared to DHT.
Clinical significance of androgens in breast cancer
Many researchers have examined the effects of androgen on breast cancer cell proliferation, and both pro- and antiproliferative effects have been demonstrated. This discrepancy is partly due to different experimental conditions, such as different androgen structures (aromatizable or non-aromatizable) and cell lines. Most importantly, androgen action varies according to molecular subtypes, according to well-established immunohistochemical markers (luminal type: positive for ERα; HER2 type: ERα-negative and HER2-positive; TNBC: negative for ERα, PR, and HER2). ERα is affected by androgen actions in breast cancers. Androgens have antiproliferative effects on ERα-positive breast cancers and proliferative effects on ERα-negative breast cancers. In ERα-positive breast cancers, androgens suppress estrogen-dependent growth (Hickey et al. 2021), partially due to the suppressive effects of androgens/AR on ERα transactivation, as described earlier. Aromatase activity is also important; aromatizable androgens are likely to be converted to estrogens and promote the proliferation of ERα-positive breast cancers. Indeed, testosterone promotes MCF-7 breast cancer cell proliferation when the cells are cocultured with breast adipose cells with aromatase activity (Chottanapund et al. 2013). On the other hand, enobosarm, a nonsteroidal selective androgen receptor modulator/agonist, inhibits in vivo tumor growth of ERα-positive breast cancers (Ponnusamy et al. 2019). Consistent with these findings, immunohistochemical AR status correlates with prolonged disease-free and overall survival in ERα-positive breast cancer patients (reviewed in Venema et al. 2019).
Preclinical data suggest that androgens promote in vitro and in vivo tumorigenesis in ERα-negative breast cancers, especially TNBCs, while antiandrogens significantly suppress tumorigenesis (Giovannelli et al. 2019). These findings are consistent with increased androgen action in ERα-negative breast cancers, namely the molecular apocrine or luminal AR (LAR) subtypes (Farmer et al. 2005, Lehmann et al. 2011). In these subtypes, AR regulates a transcriptional program similar to ERα in luminal breast cancer cells. The proliferative effects of androgen on TNBC are closely associated with intracellular phosphorylation pathways, such as the MAPK pathway and the phosphatidylinositol-3 kinase (PI3K)/Akt pathway. AR activates the MAPK pathway and increases cell proliferation (Anestis et al. 2015). In addition, ARs form complexes with Src and PI3K and promote invasion of the TNBC cell lines, MDA-MB-231 and MDA-MB-453 (Giovannelli et al. 2019). Furthermore, PIK3CA mutations and increased Akt phosphorylation are common in TNBC, and the combined use of an AR antagonist and a PI3K inhibitor effectively suppresses the growth of TNBC cells (Lehmann et al. 2014). The expression of AR is posttranscriptionally regulated by PI3K, and the PI3K-mammalian target of rapamycin (mTOR) inhibitor, BEZ235, significantly decreases AR protein levels in BT549 cells (Cuenca-López et al. 2014). Several clinical studies targeting the AR and PI3K/Akt pathways are ongoing (Chan et al. 2019). Similar to ERα-positive breast cancers, AR status correlates with better clinical outcomes, but the tendency seems to be less clear than in ERα-positive cancers (Venema et al. 2019).
Androgens and therapeutic resistance in breast cancer
Resistance to SERMs
Although androgens suppress estrogen-dependent growth of ERα-positive breast cancer cells, androgens are also closely associated with resistance to endocrine therapies in breast cancers. For example, AR expression is increased in both tamoxifen-resistant cell lines and tamoxifen-resistant breast cancer tissues, and DHT promotes the proliferation of tamoxifen-resistant breast cancer cells both in vitro and in vivo (De Amicis et al. 2010, Chia et al. 2019). Furthermore, relatively higher expression of AR compared to ERα (AR:ERα ratio ≥ 2) correlates with shorter disease-free and disease-specific survival in ERα-positive breast cancers (Cochrane et al. 2014). On the other hand, the immunohistochemical AR status in primary breast carcinoma tissues correlates with longer disease-free and overall survival in breast cancer patients receiving endocrine therapies (SERM: 71.8%; SERM followed by AI: 25.2%; AI: 2.9%) (Park et al. 2012). This suggests that AR/ERα interaction, rather than pure AR action, is more closely related to resistance to tamoxifen.
Resistance to AIs
Intratumoral DHT synthesis is increased following AI treatment, as described earlier. Therefore, several researchers investigated AR expression and its correlation with resistance to AIs. According to Chanplakorn et al. (2011), AR expression increases significantly after 3 months of neoadjuvant AI treatment. Furthermore, AR expression is maintained in recurrent breast cancer tissues after AI treatment, while ERα and PR expression levels are significantly downregulated (Fujii et al. 2014). The expression of prostate-specific antigen, a representative androgen-induced gene, is increased in recurrent tissues. In addition, a recent transcriptional analysis revealed an increased ratio of AR:ERα signaling pathway activities in patients failing AI therapy (Bleach et al. 2021). These findings suggest that increased androgen action is closely linked to AI resistance. However, the correlation between AR status and the efficacy of adjuvant AI treatment is still under discussion, as opposite findings have also been reported. For instance, a prospective cohort study showed that the immunohistochemical AR status in primary breast carcinoma tissues correlates with longer disease-free survival in the patients treated with AIs (Elebro et al. 2015). However, AR status does not serve as a predictive marker for letrozole treatment (Kensler et al. 2019). Considering these findings, androgen action may be increased but modified by loss of estrogen signaling in the process of acquired AI resistance. The modified androgen action may be similar to the actions in the molecular apocrine or LAR subtypes; both loss of estrogen signaling and increased androgen signaling are common in both situations (Fig. 2). Indeed, in the T-47D-derived AI-resistant model with lost ERα expression established by Fujii et al. (2014), the expression profile of androgen-induced genes is different from the parental T-47D cells. In addition, overexpression of AR results in resistance to AI (anastrozole) in MCF-7 cells, and AR collaborates with ERα to regulate estrogen-induced genes in resistant cells (Rechoum et al. 2014). On the other hand, antiandrogens (bicalutamide or enzalutamide) restore the sensitivity to AIs in an AI-resistant model (Creevey et al. 2019).
Possible relationship between androgen action and aromatase inhibitor (AI) resistance. Androgen action increases AI treatment due to increased DHT synthesis and decreased estrogen action. In the process of acquiring AI resistance, androgen action becomes similar to that of molecular apocrine or luminal androgen receptor (LAR) subtypes. Arom; aromatase.
Citation: Endocrine Oncology 2, 1; 10.1530/EO-22-0048
As described earlier, DHT is metabolized to 3β-diol by 17βHSD5. In addition, 3βHSD type 1 (3βHSD1) is also expressed in breast cancer cells and contributes to DHT metabolism to 3β-diol. Of note, 3β-diol can activate ERα activity. The expression of 3βHSD1 is increased in response to estradiol depletion, and 3β-diol promotes the proliferation of MCF-7 breast cancer cells in an ERα-dependent fashion (Hanamura et al. 2013). Furthermore, E10-V1 and E10-V2 cells, established by Hanamura et al., are AI-resistant. The expression of 17βHSD5 and 3βHSD1 is increased, and the cells exhibit 3β-diol-dependent and ERα-dependent growth. Consistent with these findings, ERα activity correlates with 5αRed1 and 3βHSD1expression (Hanamura et al. 2014).
Resistance to cyclin D/cyclin-dependent kinase (CDK) 4 and 6 inhibitors
The cyclin D/cyclin-dependent kinase (CDK) 4 and 6/retinoblastoma protein (Rb) pathway has been implicated in the proliferation of breast cancer cells. CDK4/6 inhibitors have recently become available for the treatment of metastatic ERα-positive/HER2-negative breast cancers (Pernas et al. 2018). However, de novo and acquired resistance to the drugs are common. Androgens may contribute to CDK4/6 inhibitor resistance. In a CDK4/6 inhibitor palbociclib-resistant model established by Ji et al. (2019), expression of AR was upregulated, while ERα signaling was suppressed. Interestingly, inhibition of AR with enzalutamide restored sensitivity to palbociclib. On the other hand, recent preclinical data demonstrated the efficacy of CDK4/6 inhibitors toward TNBCs, especially the LAR subtype. MDA-MB-453 LAR-type breast cancer cells are highly sensitive to CDK4/6 inhibitors (Asghar et al. 2017), and enzalutamide enhances the efficacy of palbociclib in AR-positive/RB-proficient TNBC cells (Liu et al. 2017).
Resistance to radiation
Expression of AR seems to correlate with recurrence after radiation (Speers et al. 2017), although the in vitro or in vivo data do not support this correlation well. Interestingly, 17βHSD5, which is frequently expressed in breast carcinoma tissues and serves as a testosterone and PGF2α-producing enzyme, promotes radiation resistance in DU145 prostate cancer cells (Sun et al. 2016).
Androgen action in breast cancer stromal cells
Solid tumors are composed of not only cancer cells but various types of stromal cells, including fibroblasts, lymphocytes, and macrophages. Tumor-infiltrating lymphocytes (TILs) are important in the response to chemotherapy and immune checkpoint inhibitors (Paijens et al. 2021), and the regulation of lymphocyte infiltration in breast carcinoma is one of the main concerns. Several studies demonstrated the correlation between AR expression and lymphocyte infiltration. For instance, AR expression is negatively correlated with CD4-positive and CD8-positive T cell infiltration in ERα-positive breast cancers (Okano et al. 2019). Similarly, in HER2-positive breast cancer cases, AR status is inversely correlated with CD3-positive and CD8-positive T cell infiltration. This tendency is detected in ERα-positive cases but not in ERα-negative cases (van Rooijen et al. 2018). Conversely, in TNBC breast cancers, a significant positive correlation between AR and CD3-positive T cell infiltration was observed (Elghazawy et al. 2021). These findings suggest that androgens have opposite effects on intratumoral T cell infiltration in ERα-positive and ERα-negative breast cancers. Similarly, androgens regulate TILs in prostatic hyperplasia and prostate cancers, and T cell infiltration into prostate tissues is induced by androgen deprivation therapy, suggesting negative regulatory effects of androgen on T cell infiltration in prostate tissues (Özdemir & Dotto 2019).
Intratumoral macrophages (tumor-associated macrophages; TAMs) are also a major component of the breast cancer microenvironment and promote breast cancer progression by secreting pro-tumor cytokines or chemokines (Yamaguchi et al. 2021a ). A recent study showed that macrophages express AR and play pivotal roles in human diseases, including breast cancers (Yamaguchi et al. 2021b ). Therefore, intratumoral DHT may affect not only breast carcinoma cells but also TAMs. Although the significance of androgen action in TAMs in breast cancers is not well understood, we previously demonstrated that the 5αRed1-positive/higher macrophage infiltration phenotype significantly correlates with worse clinical outcomes in breast cancer patients (Yamaguchi et al. 2021a). In vitro and in vivo experiments using 4T1 murine breast cancer cells and RAW264 macrophages revealed that androgens enhance the pro-tumorigenic effects of macrophages (Yamaguchi et al. 2021a). Androgen actions in the breast cancer microenvironment are important for understanding androgen actions in breast cancers.
Membrane androgen receptors in breast cancers
In addition to the induction of transcription by nuclear AR, androgens activate intracellular signaling by increasing second messengers such as Ca2+ and cAMP in a few seconds (Foradori et al. 2008). This nongenomic action may be mediated by cell membrane-anchored proteins (membrane-associated androgen receptors; mARs) rather than classical nuclear ARs. Activated intracellular signaling can be detected in AR-negative DU-145 and PC-3 prostate cancer cells (Thomas 2019). To date, four proteins have been identified as mARs, including ZRT-and Irt-like protein 9 (ZIP9), oxoeicosanoid receptor 1 (OXER), G protein-coupled receptor class C group 6 member A (GPRC6A), and transient receptor potential cation channel subfamily M member 8 (TRPM8) (Fig. 3).
Schematic of possible roles of membrane androgen receptors. ZIP9, OXER1, GPRC6A, and TRPM8 are representative membrane androgen receptors that mediate intracellular signaling, such as MAPK (ERK1/2), PI3K, mTOR, and Akt signaling to promote breast cancer progression.
Citation: Endocrine Oncology 2, 1; 10.1530/EO-22-0048
ZIP9 is a member of the 14 ZIP protein family and serves as a transporter of Zn2+ across membranes from the extracellular compartment into the cytoplasm or from the cytoplasm into organelles, such as the Golgi body (Cousins et al. 2006). ZIP9 is a mAR in the ovary of Atlantic croaker (Braun & Thomas 2003), and testosterone has a higher affinity for ZIP9 than DHT or androstenedione (Thomas et al. 2018). ZIP9 is coupled to inhibitory Gα proteins (Gαi) and activates the MAPK (extracellular signal-regulated kinase (ERK) 1/2) pathway to promote tumors (Aguirre-Portolés et al. 2021). Interestingly, this tumorigenic effect is inhibited by classic antiandrogens, such as bicalutamide, enzalutamide, and apalutamide (Aguirre-Portolés et al. 2021). ZIP9 is expressed at a higher level in breast cancer cell lines than other membrane androgen receptors (Kalyvianaki et al. 2019). Although the role of ZIP9 in breast cancers is unclear, ZIP9 is overexpressed in breast carcinoma tissues and predicts worse prognoses in HER2-type breast cancers (Liu et al. 2020).
OXER1 is a G protein-coupled receptor activated by 5-oxoeicosatretraenoic acid (5-oxo-ETE), which is produced by 5-lipoxygenase, resulting in increased breast cancer cell proliferation (Avis et al. 2001). OXER1 promotes the migration of several cancer cell lines, including the T-47D breast cancer cell line (Kalyvianaki et al. 2021). Although the expression of OXER1 has not been thoroughly examined in breast cancer tissues, recent RNA-sequence analysis demonstrated that OXER1 expression is higher in ERα-negative breast cancers than in ERα-positive breast cancers (Masi et al. 2020). OXER1 may also serve as a molecular marker in ERα-positive/HER2-negative breast cancers of adolescents and young adults (Yi & Zhou 2020). On the other hand, testosterone acts as an antagonist of OXER1-mediated intracellular signaling (Kalyvianaki et al. 2017). Thus, androgens antagonize the effects of 5-oxo-ETE on OXER1.
GPRC6A is a G protein-coupled receptor activated by multiple ligands, including osteocalcin, l-amino acid, and anabolic steroids (Pi & Quarles 2012). Therefore, GPRC6A acts as a sensor of anabolic responses in multiple tissues. GPRC6A mediates the nongenomic actions of steroids, such as testosterone, and testosterone promotes ERK phosphorylation in HEK293 cells that stably express GPRC6A but not in control HEK293 cells (Pi et al. 2010). Of note, this activation was observed for both free testosterone and BSA-bound testosterone, which cannot penetrate the cell. The tumorigenic effects of GPRC6A have been widely studied in prostate cancer. GPRC6A expression levels are higher in VCaP and PC3 prostate cancer cells compared with expression levels in RWPE-1 normal prostate cells (Liu et al. 2016). In addition, GPRC6A promotes prostate cancer cell proliferation and migration by activating ERK and mTOR phosphorylation in response to testosterone and osteocalcin (Ye et al. 2017). To the best of our knowledge, the role of GPRC6A in breast cancer has not been examined. However, L-arginine promotes mammary epithelial cell proliferation and development of mammary glands in pubertal mice through GPRC6A/PI3K/AKT/mTOR signaling (Ge et al. 2022). In humans, GPRC6A gene polymorphisms have been reported, consisting mostly of KGKY insertion/deletion in the third intracellular loop (GPRC6AICL3_KGKY) (Ye et al. 2019). These polymorphisms are gain-of-function polymorphisms (Pi et al. 2020).
Activation of TRPM8 ion channels causes Na+ and Ca2+ entry into the cells (Andersen et al. 2014). TRPM8 is activated at 15–25°C and functions as a transducer of cold temperature (Yee 2015). TRPM8 interacts with testosterone and testosterone activates a TRPM8-mediated Ca2+ response (Asuthkar et al. 2015). Interestingly, classic AR interacts with TRPM8 and modulates channel activity, suggesting the interplay between the membrane and classic ARs (Grolez et al. 2019). TRPM8 promotes EMT in breast cancer cells (Liu et al. 2014), and N-(3-aminopropyl)-2-{[(3-methylphenyl) methyl]oxy}(20)-N-(2-thienylmethyl)benzamide, a TRPM8 inhibitor, suppresses proliferation and migration of breast cancer cell lines (Yapa et al. 2018). In addition, expression of TRPM8 may be increased and is associated with larger tumor size (Liu et al. 2014), especially in breast carcinoma tissues, and TRPM8 is expressed more often in basal type breast cancers compared with the expression in other subtypes (Yapa et al. 2018).
Conclusion
The actions of androgen in breast cancers are still largely unclear, although they have been the focus of many investigations. However, a growing body of evidence supports the association of androgen with breast cancer biology. The integration of knowledge from past and recent studies is important for improving endocrine therapies and identifying new therapeutic targets in androgen-dependent breast cancers.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Funding
This work was partly supported by JSPS KAKENHI Grant number 19K09065 and 19K07410.
References
Aguirre-Portolés C, Payne R, Trautz A, Foskett JK, Natale CA, Seykora JT & Ridky TW 2021 ZIP9 is a druggable determinant of sex differences in melanoma. Cancer Research 81 5991–6003. (https://doi.org/10.1158/0008-5472.CAN-21-0982)
Amaral C, Augusto TV, Almada M, Cunha SC, Correia-da-Silva G & Teixeira N 2020 The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with exemestane. Biochimica et Biophysica Acta: Molecular Basis of Disease 1866 165661. (https://doi.org/10.1016/j.bbadis.2019.165661)
Andersen HH, Olsen RV, Møller HG, Eskelund PW, Gazerani P & Arendt-Nielsen L 2014 A review of topical high-concentration L-menthol as a translational model of cold allodynia and hyperalgesia. European Journal of Pain 18 315–325. (https://doi.org/10.1002/j.1532-2149.2013.00380.x)
Anestis A, Karamouzis MV, Dalagiorgou G & Papavassiliou AG 2015 Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treatment Reviews 41 547–553. (https://doi.org/10.1016/j.ctrv.2015.04.009)
Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L & Young A et al.2017 Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clinical Cancer Research 23 5561–5572. (https://doi.org/10.1158/1078-0432.CCR-17-0369)
Asuthkar S, Elustondo PA, Demirkhanyan L, Sun X, Baskaran P, Velpula KK, Thyagarajan B, Pavlov EV & Zakharian E 2015 The TRPM8 protein is a testosterone receptor: I. Biochemical evidence for direct TRPM8-testosterone interactions. Journal of Biological Chemistry 290 2659–2669. (https://doi.org/10.1074/jbc.M114.610824)
Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J, Das R, Jett M & Mulshine JL 2001 Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB Journal 15 2007–2009. (https://doi.org/10.1096/fj.00-0866fje)
Bleach R, Madden SF, Hawley J, Charmsaz S, Selli C, Sheehan KM, Young LS, Sims AH, Souček P & Hill AD et al.2021 Steroid ligands, the forgotten triggers of nuclear receptor action; implications for acquired resistance to endocrine therapy. Clinical Cancer Research 27 3980–3989. (https://doi.org/10.1158/1078-0432.CCR-20-4135)
Braun AM & Thomas P 2003 Androgens inhibit estradiol-17beta synthesis in Atlantic croaker (Micropogonias undulatus) ovaries by a nongenomic mechanism initiated at the cell surface. Biology of Reproduction 69 1642–1650. (https://doi.org/10.1095/biolreprod.103.015479)
Chan JJ, Tan TJY & Dent RA 2019 Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Therapeutic Advances in Medical Oncology 11 1758835919880429. (https://doi.org/10.1177/1758835919880429)
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Wang L, Chan MS, Wing L, Yiu CC, Chow LW & Sasano H 2011 Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. Hormones and Cancer 2 73–81. (https://doi.org/10.1007/s12672-010-0062-2)
Chia K, Milioli H, Portman N, Laven-Law G, Coulson R, Yong A, Segara D, Parker A, Caldon CE & Deng N et al.2019 Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocrine-Related Cancer 26 251–264. (https://doi.org/10.1530/ERC-18-0333)
Choi MH 2018 Mass spectrometry-based metabolic signatures of sex steroids in breast cancer. Molecular and Cellular Endocrinology 466 81–85. (https://doi.org/10.1016/j.mce.2017.09.023)
Chottanapund S, Van Duursen MB, Navasumrit P, Hunsonti P, Timtavorn S, Ruchirawat M & Van den Berg M 2013 Effect of androgens on different breast cancer cells co-cultured with or without breast adipose fibroblasts. Journal of Steroid Biochemistry and Molecular Biology 138 54–62. (https://doi.org/10.1016/j.jsbmb.2013.03.007)
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A & Guerrero J et al.2014 Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research 16 R7. (https://doi.org/10.1186/bcr3599)
Cousins RJ, Liuzzi JP & Lichten LA 2006 Mammalian zinc transport, trafficking, and signals. Journal of Biological Chemistry 281 24085–24089. (https://doi.org/10.1074/jbc.R600011200)
Creevey L, Bleach R, Madden SF, Toomey S, Bane FT, Varešlija D, Hill AD, Young LS & McIlroy M 2019 Altered steroid milieu in AI-resistant breast cancer facilitates AR mediated gene-expression associated with poor response to therapy. Molecular Cancer Therapeutics 18 1731–1743. (https://doi.org/10.1158/1535-7163.MCT-18-0791)
Cuenca-López MD, Montero JC, Morales JC, Prat A, Pandiella A & Ocana A 2014 Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 14 302. (https://doi.org/10.1186/1471-2407-14-302)
D’Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ & Sartorius CA et al.2016 Cooperative dynamics of AR and ER activity in breast cancer. Molecular Cancer Research 14 1054–1067. (https://doi.org/10.1158/1541-7786.MCR-16-0167)
De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A & Lewis MT et al.2010 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Research and Treatment 121 1–11. (https://doi.org/10.1007/s10549-009-0436-8)
De Amicis F, Chiodo C, Morelli C, Casaburi I, Marsico S, Bruno R, Sisci D, Andò S & Lanzino M 2019 AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells. BMC Cancer 19 1038. (https://doi.org/10.1186/s12885-019-6262-4)
Elebro K, Borgquist S, Simonsson M, Markkula A, Jirström K, Ingvar C, Rose C & Jernström H 2015 Combined androgen and estrogen receptor status in breast cancer: treatment prediction and prognosis in a population-based prospective cohort. Clinical Cancer Research 21 3640–3650. (https://doi.org/10.1158/1078-0432.CCR-14-2564)
Elghazawy H, Bakkach J, Helal T, Aref AM, Kelany M, Abdallah LE, Abdelbakey FS, Ali D, Ali DZ & Ahmed MO et al.2021 Clinico-pathological relationship between androgen receptor and tumour infiltrating lymphocytes in triple negative breast cancer. Ecancermedicalscience 15 1317. (https://doi.org/10.3332/ecancer.2021.1317)
Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D & Goldstein D et al.2005 Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24 4660–4671. (https://doi.org/10.1038/sj.onc.1208561)
Foradori CD, Weiser MJ & Handa RJ 2008 Non-genomic actions of androgens. Frontiers in Neuroendocrinology 29 169–181. (https://doi.org/10.1016/j.yfrne.2007.10.005)
Fujii R, Hanamura T, Suzuki T, Gohno T, Shibahara Y, Niwa T, Yamaguchi Y, Ohnuki K, Kakugawa Y & Hirakawa H et al.2014 Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology 144 513–522. (https://doi.org/10.1016/j.jsbmb.2014.08.019)
Garcia-Velasco JA, Moreno L, Pacheco A, Guillén A, Duque L, Requena A & Pellicer A 2005 The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertility and Sterility 84 82–87. (https://doi.org/10.1016/j.fertnstert.2005.01.117)
Ge Y, Li F, He Y, Cao Y, Guo W, Hu G, Liu J & Fu S 2022 L-arginine stimulates the proliferation of mouse mammary epithelial cells and the development of mammary gland in pubertal mice by activating the GPRC6A/PI3K/AKT/mTOR signalling pathway. Journal of Animal Physiology and Animal Nutrition [epub]. (https://doi.org/10.1111/jpn.13730)
Giovannelli P, Di Donato M, Auricchio F, Castoria G & Migliaccio A 2019 Androgens induce invasiveness of triple negative breast cancer cells Through AR/Src/PI3-K complex assembly. Scientific Reports 9 4490. (https://doi.org/10.1038/s41598-019-41016-4)
Grolez GP, Gordiendko DV, Clarisse M, Hammadi M, Desruelles E, Fromont G, Prevarskaya N, Slomianny C & Gkika D 2019 TRPM8-androgen receptor association within lipid rafts promotes prostate cancer cell migration. Cell Death and Disease 10 652. (https://doi.org/10.1038/s41419-019-1891-8)
Hanamura T, Niwa T, Nishikawa S, Konno H, Gohno T, Tazawa C, Kobayashi Y, Kurosumi M, Takei H & Yamaguchi Y et al.2013 Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism. Breast Cancer Research and Treatment 139 731–740. (https://doi.org/10.1007/s10549-013-2595-x)
Hanamura T, Niwa T, Gohno T, Kurosumi M, Takei H, Yamaguchi Y, Ito K & Hayashi S 2014 Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers. Breast Cancer Research and Treatment 143 69–80. (https://doi.org/10.1007/s10549-013-2788-3)
Hanamura T, Ito T, Kanai T, Maeno K, Shimojo Y, Uehara T, Suzuki T, Hayashi S & Ito K 2016 Human 3β-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations. Cancer Medicine 5 1405–1415. (https://doi.org/10.1002/cam4.708)
Hashimoto C, Miki Y, Tanaka S, Takagi K, Fue M, Doe Z, Li B, Yaegashi N, Suzuki T & & Ito K 2018 17β-Hydroxysteroid dehydrogenase type 2 expression is induced by androgen signaling in endometrial cancer. International Journal of Molecular Sciences 19 1139. (https://doi.org/10.3390/ijms19041139)
Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J & Ebrahimie E et al.2021 The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nature Medicine 27 310–320. (https://doi.org/10.1038/s41591-020-01168-7)
Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL & Carroll JS et al.2016 Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Research 76 5881–5893. (https://doi.org/10.1158/0008-5472.CAN-15-3372)
Ji W, Shi Y, Wang X, He W, Tang L, Tian S, Jiang H, Shu Y & Guan X 2019 Combined androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib. International Journal of Biological Sciences 15 522–532. (https://doi.org/10.7150/ijbs.30572)
Kalyvianaki K, Gebhart V, Peroulis N, Panagiotopoulou C, Kiagiadaki F, Pediaditakis I, Aivaliotis M, Moustou E, Tzardi M & Notas G et al.2017 Antagonizing effects of membrane-acting androgens on the eicosanoid receptor OXER1 in prostate cancer. Scientific Reports 7 44418. (https://doi.org/10.1038/srep44418)
Kalyvianaki K, Panagiotopoulos AA, Malamos P, Moustou E, Tzardi M, Stathopoulos EN, Ioannidis GS, Marias K, Notas G & Theodoropoulos PA et al.2019 Membrane androgen receptors (OXER1, GPRC6A AND ZIP9) in prostate and breast cancer: a comparative study of their expression. Steroids 142 100–108. (https://doi.org/10.1016/j.steroids.2019.01.006)
Kalyvianaki K, Drosou I, Notas G, Castanas E & Kampa M 2021 Enhanced OXER1 expression is indispensable for human cancer cell migration. Biochemical and Biophysical Research Communications 584 95–100. (https://doi.org/10.1016/j.bbrc.2021.11.024)
Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B & Colleoni M et al.2019 Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Research 21 30. (https://doi.org/10.1186/s13058-019-1118-z)
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y & Pietenpol JA 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121 2750–2767. (https://doi.org/10.1172/JCI45014)
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H & Arteaga CL et al.2014 PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research 16 406. (https://doi.org/10.1186/s13058-014-0406-x)
Li T, Zhang W & Lin SX 2020 Steroid enzyme and receptor expression and regulations in breast tumor samples – a statistical evaluation of public data. Journal of Steroid Biochemistry and Molecular Biology 196 105494. (https://doi.org/10.1016/j.jsbmb.2019.105494)
Liu J, Chen Y, Shuai S, Ding D, Li R & Luo R 2014 TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK-3β pathway. Tumour Biology 35 8969–8977. (https://doi.org/10.1007/s13277-014-2077-8)
Liu M, Zhao YY, Yang F, Wang JY, Shi XH, Zhu XQ, Xu Y, Wei D, Sun L & Zhang YG et al.2016 Evidence for a role of GPRC6A in prostate cancer metastasis based on case-control and in vitro analyses. European Review for Medical and Pharmacological Sciences 20 2235–2248.
Liu CY, Lau KY, Hsu CC, Chen JL, Lee CH, Huang TT, Chen YT, Huang CT, Lin PH & Tseng LM 2017 Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS ONE 12 e0189007. (https://doi.org/10.1371/journal.pone.0189007)
Liu L, Yang J & Wang C 2020 Analysis of the prognostic significance of solute carrier (SLC) family 39 genes in breast cancer. Bioscience Reports 40 BSR20200764. (https://doi.org/10.1042/BSR20200764)
Masi M, Garattini E, Bolis M, Di Marino D, Maraccani L, Morelli E, Grolla AA, Fagiani F, Corsini E & Travelli C et al.2020 OXER1 and RACK1-associated pathway: a promising drug target for breast cancer progression. Oncogenesis 9 105. (https://doi.org/10.1038/s41389-020-00291-x)
Okano M, Oshi M, Butash AL, Asaoka M, Katsuta E, Peng X, Qi Q, Yan L & Takabe K 2019 Estrogen receptor positive breast cancer with high expression of androgen receptor has less cytolytic activity and worse response to neoadjuvant chemotherapy but better survival. International Journal of Molecular Sciences 20 2655. (https://doi.org/10.3390/ijms20112655)
Özdemir BC & Dotto GP 2019 Sex hormones and anticancer immunity. Clinical Cancer Research 25 4603–4610. (https://doi.org/10.1158/1078-0432.CCR-19-0137)
Paijens ST, Vledder A, de Bruyn M & Nijman HW 2021 Tumor-infiltrating lymphocytes in the immunotherapy era. Cellular and Molecular Immunology 18 842–859. (https://doi.org/10.1038/s41423-020-00565-9)
Park S, Park HS, Koo JS, Yang WI, Kim SI & Park BW 2012 Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Research and Treatment 133 311–320. (https://doi.org/10.1007/s10549-011-1950-z)
Pernas S, Tolaney SM, Winer EP & Goel S 2018 CDK4/6 inhibition in breast cancer: current practice and future directions. Therapeutic Advances in Medical Oncology 10 1758835918786451. (https://doi.org/10.1177/1758835918786451)
Pi M & Quarles LD 2012 Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology 153 2062–2069. (https://doi.org/10.1210/en.2011-2117)
Pi M, Parrill AL & Quarles LD 2010 GPRC6A mediates the non-genomic effects of steroids. Journal of Biological Chemistry 285 39953–39964. (https://doi.org/10.1074/jbc.M110.158063)
Pi M, Xu F, Ye R, Nishimoto SK, Kesterson RA, Williams RW, Lu L & Quarles LD 2020 Humanized GPRC6AKGKY is a gain-of-function polymorphism in mice. Scientific Reports 10 11143. (https://doi.org/10.1038/s41598-020-68113-z)
Ponnusamy S, Asemota S, Schwartzberg LS, Guestini F, McNamara KM, Pierobon M, Font-Tello A, Qiu X, Xie Y & Rao PK et al.2019 Androgen receptor is a non-canonical inhibitor of wild-type and mutant estrogen receptors in hormone receptor-positive breast cancers. iScience 21 341–358. (https://doi.org/10.1016/j.isci.2019.10.038)
Rahim B & O’Regan R 2017 AR signaling in breast cancer. Cancers 9 21. (https://doi.org/10.3390/cancers9030021)
Rechoum Y, Rovito D, Iacopetta D, Barone I, Andò S, Weigel NL, O’Malley BW, Brown PH & Fuqua SA 2014 AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. Breast Cancer Research and Treatment 147 473–485. (https://doi.org/10.1007/s10549-014-3082-8)
Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H & Evans DB et al.2008 Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocrine-Related Cancer 15 113–124. (https://doi.org/10.1677/ERC-07-0092)
Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG & Kothari V et al.2017 Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. NPJ Breast Cancer 3 29. (https://doi.org/10.1038/s41523-017-0038-2)
Spinola PG, Marchetti B, Mérand Y, Bélanger A & Labrie F 1988 Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors. Breast Cancer Research and Treatment 12 287–296. (https://doi.org/10.1007/BF01811241)
Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B & Penning TM 2004 Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. Journal of Biological Chemistry 279 10784–10795. (https://doi.org/10.1074/jbc.M313308200)
Sun SQ, Gu X, Gao XS, Li Y, Yu H, Xiong W, Yu H, Wang W, Li Y & Teng Y et al.2016 Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation, Oncotarget 7 48050–48058. Erratum in: Oncotarget 2020 11 1575. (https://doi.org/10.18632/oncotarget.27542)
Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T & & Sasano H 2001 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. Journal of Clinical Endocrinology and Metabolism 86 2250–2257. (https://doi.org/10.1210/jcem.86.5.7444)
Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N & Sasano H 2005 Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer 12 701–720. (https://doi.org/10.1677/erc.1.00834)
Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S & Sasano H 2007 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. International Journal of Cancer 120 285–291. (https://doi.org/10.1002/ijc.22317)
Suzuki T, Miki Y, Takagi K, Hirakawa H, Moriya T, Ohuchi N & Sasano H 2010 Androgens in human breast carcinoma. Medical Molecular Morphology 43 75–81. (https://doi.org/10.1007/s00795-010-0494-3)
Takagi K, Miki Y, Nagasaki S, Hirakawa H, Onodera Y, Akahira J, Ishida T, Watanabe M, Kimijima I & Hayashi S et al.2010 Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocrine-Related Cancer 17 415–430. (https://doi.org/10.1677/ERC-09-0257)
Takagi K, Miki Y, Ishida T, Sasano H & Suzuki T 2018 The interplay of endocrine therapy, steroid pathways and therapeutic resistance: importance of androgen in breast carcinoma. Molecular and Cellular Endocrinology 466 31–37. (https://doi.org/10.1016/j.mce.2017.09.011)
Tanaka S, Miki Y, Hashimoto C, Takagi K, Doe Z, Li B, Yaegashi N, Suzuki T & & Ito K 2015 The role of 5α-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. Molecular and Cellular Endocrinology 401 56–64. (https://doi.org/10.1016/j.mce.2014.11.022)
Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD & Sparano JA 2013 Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119 1140–1148. (https://doi.org/10.1002/cncr.27819)
Thomas P 2019 Membrane androgen receptors unrelated to nuclear steroid receptors. Endocrinology 160 772–781. (https://doi.org/10.1210/en.2018-00987)
Thomas P, Converse A & Berg HA 2018 ZIP9, a novel membrane androgen receptor and zinc transporter protein. General and Comparative Endocrinology 257 130–136. (https://doi.org/10.1016/j.ygcen.2017.04.016)
Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y & Nakagawa H 2008 Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Science 99 81–86. (https://doi.org/10.1111/j.1349-7006.2007.00656.x)
van Rooijen JM, Qiu SQ, Timmer-Bosscha H, van der Vegt B, Boers JE, Schröder CP & de Vries EGE 2018 Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer. European Journal of Cancer 103 52–60. (https://doi.org/10.1016/j.ejca.2018.08.001)
Venema CM, Bense RD, Steenbruggen TG, Nienhuis HH, Qiu SQ, van Kruchten M, Brown M, Tamimi RM, Hospers GAP & Schröder CP et al.2019 Consideration of breast cancer subtype in targeting the androgen receptor. Pharmacology and Therapeutics 200 135–147. (https://doi.org/10.1016/j.pharmthera.2019.05.005)
Waks AG & Winer EP 2019 Breast cancer treatment: a review. JAMA 321 288–300. (https://doi.org/10.1001/jama.2018.19323)
Weber H & Garabedian MJ 2018 The mediator complex in genomic and non-genomic signaling in cancer. Steroids 133 8–14. (https://doi.org/10.1016/j.steroids.2017.11.007)
Xu D, Zhang Y & Jin F 2021 The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining. BMC Cancer 21 1321. (https://doi.org/10.1186/s12885-021-09040-8)
Yamaguchi M, Takagi K, Sato M, Sato A, Miki Y, Onodera Y, Miyashita M, Sasano H & Suzuki T 2021a Androgens enhance the ability of intratumoral macrophages to promote breast cancer progression. Oncology Reports 46 188. (https://doi.org/10.3892/or.2021.8139)
Yamaguchi M, Takagi K, Narita K, Miki Y, Onodera Y, Miyashita M, Sasano H & Suzuki T 2021b Stromal CCL5 promotes breast cancer progression by interacting with CCR3 in tumor cells. International Journal of Molecular Sciences 22 1918. (https://doi.org/10.3390/ijms22041918)
Yapa KTDS, Deuis J, Peters AA, Kenny PA, Roberts-Thomson SJ, Vetter I & Monteith GR 2018 Assessment of the TRPM8 inhibitor AMTB in breast cancer cells and its identification as an inhibitor of voltage gated sodium channels. Life Sciences 198 128–135. (https://doi.org/10.1016/j.lfs.2018.02.030)
Ye R, Pi M, Cox JV, Nishimoto SK & Quarles LD 2017 CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model. Journal of Experimental and Clinical Cancer Research 36 90. (https://doi.org/10.1186/s13046-017-0561-x)
Ye R, Pi M, Nooh MM, Bahout SW & Quarles LD 2019 Human GPRC6A mediates testosterone-induced mitogen-activated protein kinases and mTORC1 signaling in prostate cancer cells. Molecular Pharmacology 95 563–572. (https://doi.org/10.1124/mol.118.115014)
Yee NS 2015 Roles of TRPM8 ion channels in cancer: proliferation, survival, and invasion. Cancers 7 2134–2146. (https://doi.org/10.3390/cancers7040882)
Yi S & Zhou W 2020 Tumorigenesis-related key genes in adolescents and young adults with HR(+)/HER2(-) breast cancer. International Journal of Clinical and Experimental Pathology 13 2701–2709.
Yin YD, Fu M, Brooke DG, Heinrich DM, Denny WA & Jamieson SM 2014 The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17β-estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer. Frontiers in Oncology 4 159. (https://doi.org/10.3389/fonc.2014.00159)
Yoda T, Kikuchi K, Miki Y, Onodera Y, Hata S, Takagi K, Nakamura Y, Hirakawa H, Ishida T & Suzuki T et al.2015 11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer. Molecular and Cellular Endocrinology 413 236–247. (https://doi.org/10.1016/j.mce.2015.07.008)
Zhang YP, Na WT, Dai XQ, Li RF, Wang JX, Gao T, Zhang WB & Xiang C 2021 Over-expression of SRD5A3 and its prognostic significance in breast cancer. World Journal of Surgical Oncology 19 260. (https://doi.org/10.1186/s12957-021-02377-1)
